Abstract
The circadian clock is regulated at the molecular level by feedback circuits of a group of genes known as "clock genes", which establish a mechanism that controls circadian cellular physiology to maintain the balance between cell proliferation, response to DNA damage and apoptosis. Alterations in the expression of clock genes due to genetic or epigenetic mechanisms have been associated with multiple diseases including cancer. Even some clock genes such as the Per1, Per2, Bmal1 genes have been proposed as tumor suppressor genes, with a relevant role during carcinogenesis. At the molecular level, multiple mechanisms of molecular control have been described to link circadian transcription, cell cycle control, and tumorigenesis. In addition, recent findings describe an epigenetic control of circadian transcription, at the level of DNA methylation as well as in the modifications of histones. However, the link between the circadian epigenome and cancer remains unclear. In this article, we review the evidence that suggests a relationship between alterations in the expression of clock genes, with the development of cancer, from the epigenetic landscape.
Similar content being viewed by others
References
Alam H, Gu B, Lee MG (2015) Histone methylation modifiers in cellular signaling pathways. Cell Mol Life Sci 72:4577–4592
Alenghat T, Meyers K, Mullican SE, Leitner K, Adeniji-Adele A, Avila J, Bućan M, Ahima RS, Kaestner KH, Lazar MA (2008) Nuclear receptor corepressor and histone deacetylase 3 govern circadian metabolic physiology. Nature 456:997–1000
Archer SY, Meng S, Shei A, Hodin R (1998) p21WAF1 is required for butyrate-mediated growth inhibition of colon cancer cells. Proc Natl Acad Sci USA 95:6791–6796
Baylin SB (2005) DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2:4–11
Blask DE, Hill SM, Dauchy RT, Xiang S, Yuan L, Duplessis T, Mao L, Dauchy E, Sauer LA (2011) Circadian regulation of molecular, dietary, and metabolic signaling mechanisms of human breast cancer growth by the nocturnal melatonin signal and the consequences of its disruption by light at night. J Pineal Res 51:259–269
Brandi G, Calabrese C, Pantaleo MA, Morselli Labate A, Di Febo G, Hakim R, De Vivo A, Di Marco MC, Biasco G (2004) Circadian variations of rectal cell proliferation in patients affected by advanced colorectal cancer. Cancer Lett 208:193–196
Cao Q, Gery S, Dashti A, Yin D, Zhou Y, Gu J, Koeffler HP (2009) A role for the clock gene per1 in prostate cancer. Cancer Res 69:7619–7625
Cash E, Sephton SE, Chagpar AB, Spiegel D, Rebholz WN, Zimmaro LA, Tillie JM, Dhabhar FS (2015) Circadian disruption and biomarkers of tumor progression in breast cancer patients awaiting surgery. Brain Behav Immun 48:102–114
Chen ST, Choo KB, Hou MF, Yeh KT, Kuo SJ, Chang JG (2005) Deregulated expression of the PER1, PER2 and PER3 genes in breast cancers. Carcinogenesis 26:1241–1246
Chen YJ, Chen CM, Twu NF, Yen MS, Lai CR, Wu HH, Wang PH, Yuan CC (2009) Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patients. Virchows Arch 455:431–440
Chi P, Allis C, Wang GG (2010) Covalent histone modifications: miswritten, misinterpreted, and miserased in human cancers. Nat Rev Cancer 10:457–469
Chodaparambil JV, Edayathumangalam RS, Bao Y, Park YJ, Luger K (2006) Nucleosome structure and function. Ernst Schering Res Found Workshop 57:29–46
Costello JF, Frühwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, Wright FA, Feramisco JD, Peltomäki P et al (2000) Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 24:132–138
Cress WD, Seto E (2000) Histone deacetylases, transcriptional control, and cancer. J Cell Physiol 184:1–16
Crosio C, Cermakian N, Allis CD, Sassone-Corsi P (2000) Light induces chromatin modification in cells of the mammalian circadian clock. Nat Neurosci 3:1241–1247
Curtis AM, Seo SB, Westgate EJ, Rudic RD, Smyth EM, Chakravarti D, FitzGerald GA, McNamara P (2004a) Histone acetyltransferase-dependent chromatin remodeling and the vascular clock. J Biol Chem 279:7091–7097
Dai H, Zhang L, Cao M, Song F, Zheng H, Zhu X, Wei Q, Zhang W, Chen K (2011) The role of polymorphisms in circadian pathway genes in breast tumorigenesis. Breast Cancer Res 127:531–540
Davie JR, Moniwa M (2000) Control of chromatin remodeling. Crit Rev Eukaryot Gene Expr 10:303–325
Davis S, Mirick DK, Stevens RG (2001) Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 93:1557–1562
Doi M, Hirayama J, Sassone-Corsi P (2006) Circadian regulator CLOCK is a histone acetyltransferase. Cell 125:497–508
Dong G, Yang Q, Wang Q, Kim YI, Wood TL, Osteryoung KW, van Oudenaarden A, Golden SS (2010) Elevated ATPase activity of KaiC applies a circadian checkpoint on cell division in Synechococcus elongatus. Cell 140:529–539
Duong HA, Robles MS, Knutti D, Weitz CJ (2011) A molecular mechanism for circadian clock negative feedback. Science 332:1436–1439
Eisele L, Prinz R, Klein-Hitpass L, Nückel H, Lowinski K, Thomale J, Moeller LC, Dührsen U, Dürig J (2009) Combined PER2 and CRY1 expression predicts outcome in chronic lymphocytic leukemia. Eur J Haematol 83:320–327
Ekholm S, Reed S (2000) Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684
Elshazley M, Sato M, Hase T, Yamashita R, Yoshida K, Toyokuni S, Ishiguro F, Osada H, Sekido Y, Yokoi K et al (2012) The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma. Int J Cancer 131:2820–2831
Esteller M, Corn PG, Baylin SB, Herman JG (2001) A gene hypermethylation profile of human cancer. Cancer Res 61:3225–3229
Etchegaray JP, Lee C, Wade PA, Reppert SM (2003) Rhythmic histone acetylation underlies transcription in the mammalian circadian clock. Nature 421:177–182
Etchegaray JP, Yang X, DeBruyne JP, Peters AH, Weaver DR, Jenuwein T, Reppert SM (2006) The polycomb group protein EZH2 is required for mammalian circadian clock function. J Biol Chem 281:21209–21215
Filipski E, Li XM, Lévi F (2006) Disruption of circadian coordination and malignant growth. Cancer Causes Control 7:509–514
Fraga MF, Ballestar E, Villar-Garea A, Boix-Chornet M, Espada J, Schotta G, Bonaldi T, Haydon C, Ropero S, Petrie K et al (2005) Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer. Nat Genet 37:391–400
Fu L, Pelicano H, Liu J, Huang P, Lee CC (2002) The circadian gene Period2 plays an important role in tumor suppression and DNA damage response in vivo. Cell 111:41–50
Garcia BA, Hake SB, Diaz RL, Kauer M, Morris SA, Recht J, Shabanowitz J, Mishra N, Strahl BD, Allis CD, Hunt DF (2007) Organismal differences in post-translational modifications in histones H3 and H4. J Biol Chem 282:7641–7655
Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP (2006) The circadian gene per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell 22:375–382
Gery S, Komatsu N, Kawamata N, Miller CW, Desmond J, Virk RK, Marchevsky A, Mckenna R, Taguchi H, Koeffler HP (2007) Epigenetic silencing of the candidate tumor suppressor gene Per1 in non-small cell lung cancer. Clin Cancer Res 13:1399–1404
Glaser KB, Staver MJ, Waring JF, Stender J, Ulrich RG, Davidsen SK (2003) Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2:151–163
Grant C, Rahman F, Piekarz R, Peer C, Frye R, Robey RW, Gardner ER, Figg WD, Bates SE (2010) Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors. Expert Rev Anticancer Ther 10:997–1008
Grechez-Cassiau SV, Reed SI (2000) Regulation of G1 cyclin-dependent kinases in the mammalian cell cycle. Curr Opin Cell Biol 12:676–684
Grechez-Cassiau A, Rayet B, Guillaumond F, Teboul M, Delaunay F (2008) The circadian clock component BMAL1 is a critical regulator of p21WAF1/CIP1 expression and hepatocyte proliferation. J Biol Chem 283:4535–4542
Greene MW (2012) Circadian rhythms and tumor growth. Cancer Lett 318:115–123
Grimaldi B, Nakahata Y, Sahar S, Kaluzova M, Gauthier D, Pham K, Patel N, Hirayama J, Sassone-Corsi P (2007) Chromatin remodeling and circadian control: master regulator CLOCK is an enzyme. Cold Spring Harb Symp Quant Biol 72:105–112
Haifa Abdulhaq MD, James M, Rossetti DO (2007) The role of azacitidine in the treatment of myelodysplastic syndromes. Expert Opin Investig Drugs 16:1967–1975
Hansen J (2001) Light at night, shiftwork, and breast cancer risk. J Natl Cancer Inst 93:1513–1515
Hernández-Rosas F, Hernández-Oliveras A, Flores-Peredo L, Rodríguez G, Zarain-Herzberg A, Caba M, Santiago-García J (2018) Histone-deacetylase inhibitors induce the expression of tumor suppressor genes Per1 and Per2 in human gastric cancer cells. Oncol Lett 16:1981–1990
Hirayama J, Cardone L, Doi M, Sassone-Corsi P (2005) Common pathways in circadian and cell cycle clocks: light-dependentactivation of Fos/AP-1 in zebrafish controls CRY-1a and WEE-1. Proc Natl Acad Sci USA 102:10194–10199
Hirayama J, Sahar S, Grimaldi B, Tamaru T, Takamatsu K, Nakahata Y, Sassone-Corsi P (2007) CLOCK-mediated acetylation of BMAL1 controls circadian function. Nature 450:1086–1090
Hoffman AE, Yi CH, Zheng T, Stevens RG, Leaderer D, Zhang Y, Holford TR, Hansen J, Paulson J, Zhu Y (2010) CLOCK in breast tumorigenesis: genetic, epigenetic, and transcriptional profiling analyses. Cancer Res 70:1459–1468
Jung-Hynes B, Schmit TL, Reagan-Shaw SR, Siddiqui IA, Mukhtar H, Ahmad N (2011) Melatonin, a novel Sirt1 inhibitor, imparts antiproliferative effects against prostate cancer in vitro in culture and in vivo in TRAMP model. J Pineal Res 50:140–149
Katada S, Sassone-Corsi P (2010) The histone methyltransferase MLL1 permits the oscillation of circadian gene expression. Nat Struct Mol Biol 17:1414–1421
Katada S, Imhof A, Sassone-Corsi P (2012) Connecting threads: epigenetics and metabolism. Cell 148:24–28
Kettner NM, Katchy CA, Fu L (2014) Circadian gene variants in cancer. Ann Med 46:208–220
Kiessling S, Beaulieu-Laroche L, Blum ID, Landgraf D, Welsh DK, Storch KF, Labrecque N, Cermakian N (2017) Enhancing circadian clock function in cancer cells inhibits tumor growth. BMC Biol 15:13
Kim DH, Kim M, Kwo HJ (2003) Histone Deacetylase in carcinogenesis and its inhibitors as anti-cancer agents. Biochem Mol Biol J 36:110–119
Klose RJ, Bird AP (2006) Genomic DNA methylation: the mark and its mediators. Trends Biochem Sci 31:89–97
Kowalska E, Ripperger JA, Hoegger DC, Bruegger P, Buch T, Birchler T, Mueller A, Albrecht U, Contaldo C, Brown SA (2012) NONO couples the circadian clock to the cell cycle. Proc Natl Acad Sci USA 110:1592–1599
Kulis M, Esteller M (2010) DNA methylation and cancer. In: Zdenko H, Toshikazu U (eds) Advances in genetics, vol 70. Academic Press, New York, pp 27–56
Kuo SJ, Chen ST, Yeh KT, Hou MF, Chang YS, Hsu NC, Chang JG (2009) Disturbance of circadian gene expression in breast cancer. Virchows Arch 454:467–474
Laranjeiro R, Tamai TK, Peyric E, Krusche P, Ott S, Whitmore D (2013) Cyclin-dependent kinase inhibitor p20 controls circadian cell-cycle timing. Proc Natl Acad Sci USA 110:6835–6840
Lee CC (2006) Tumor suppression by the mammalian Period gene. Cancer Causes Control 17:525–553
Lee S, Donehower LA, Herron AJ, Moore DD, Fu L (2010a) Disrupting circadian homeostasis of sympathetic signaling promotes tumor development in mice. PLoS ONE 5:e10995
Lee Y, Lee J, Kwon I, Nakajima Y, Ohmiya Y, Son GH, Lee KH, Kim K (2010b) Coactivation of the CLOCK-BMAL1 complex by CBP mediates resetting of the circadian clock. J Cell Sci 123:3547–3557
Lee HZ, Kwitkowski VE, Del Valle PL, Ricci MS, Saber H, Habtemariam BA, Bullock J, Bloomquist E, Li SY et al (2015) FDA approval: belinostat for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Clin Cancer Res 21:2666–2670
Levi F, Okyar A, Dulong S, Innominato PF, Clairambault J, Levi F (2010) Circadian timing in cancer treatments. Annu Rev Pharmacol Toxicol 50:377–421
Lewintre EJ, Martin CR, Ballesteros CG, Montaner D, Rivera RF, Mayans JR, García-Conde J (2009) Cryptochrome-1 expression: a new prognostic marker in B-cell chronic lymphocytic leukemia. Haematologica 94:280–284
Lippman Z, May B, Yordan C, Singer T, Martienssen R (2003) Distinct mechanisms determine transposon inheritance and methylation via small interfering RNA and histone modification. PLoS Biol 1:e67
Lowrey PL, Takahashi JS (2011) Genetics of circadian rhythms in mammalian model organisms. Adv Genet 74:175–230
Luo W, Sehgal A (2005) Regulation of circadian behavioral output via a MicroRNAJAK/STAT circuit. Cell 148:765–779
Luo J, Su F, Chen D, Shiloh A, Gu W (2000) Deacetylation of p53 modulates its effect on cell growth and apoptosis. Nature 408:377–381
Masri S, Sassone-Corsi P (2010) Plasticity and specificity of the circadian epigenome. Nat Neurosci 13:1324–1329
Masri S, Cervantes M, Sassone-Corsi P (2013) The circadian clock and cell cycle: interconnected biological circuits. Curr Opin Cell Biol 25:730–734
Matsuo T, Yamaguchi S, Mitsui S, Emi A, Shimoda F, Okamura H (2003) Control mechanism of the circadian clock for timing of cell division in vivo. Science 302:255–259
Monks A, Hose CD, Pezzoli P, Kondapaka S, Vansant G, Petersen KD, Sehested M, Monforte J, Shoemaker RH (2009) Gene expression-signature of belinostat in cell lines is specific for histone deacetylase inhibitor treatment, with a corresponding signature in xenografts. Anticancer Drugs 20:682–692
Mori T, Binder B, Johnson CH (1996) Circadian gating of cell division in cyanobacteria growing with average doubling times of less than 24 hours. Proc Natl Acad Sci USA 93:10183–10188
Mormont MC, Levi F (2003) Cancer chronotherapy: principles, applications, and perspectives. Cancer 98:881–882
Mottet D, Castronovo V (2008) Histone de-acetylases: target enzymes for cancer therapy. Clin Exp Metastasis 25:183–189
Mullenders J, Fabius AW, Madiredjo M, Bernards R, Beijersbergen RL (2009) A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. PLoS ONE 4:e4798
Nakahata Y, Kaluzova M, Grimaldi B, Sahar S, Hirayama J, Chen D, Guarente LP, Sassone-Corsi P (2008) The NAD+-dependent deacetylase SIRT1 modulates CLOCK mediated chromatin remodeling and circadian control. Cell 134:329–340
Narasimamurthy R, Hatori M, Nayak SK, Liu F, Panda S, Verma IM (2012) Circadian clock protein cryptochrome regulates the expression of proinflammatory cytokines. Proc Natl Acad Sci USA 109:12662–12667
Naruse Y, Oh-hashi K, Iijima N, Naruse M, Yoshioka H, Tanaka M (2004) Circadian and light-induced transcription of clock gene Per1 depends on histone acetylation and deacetylation. Mol Cell Biol 24:6278–6287
Nebbioso A, Carafa V, Benedetti R, Altucci L (2012) Trials with “epigenetic” drugs: an update. Mol Oncol 6:657–682
Oda A, Katayose Y, Yabuuchi S, Yamamoto K, Mizuma M, Shirasou S, Onogawa T, Ohtsuka H, Yoshida H et al (2009) Clock gene mouse period2 overexpression inhibits growth of human pancreatic cancer cells and has synergistic effect with cisplatin. Anticancer Res 29:1201–1209
Panda S, Antoch MP, Miller BH, Su AI, Schook AB, Straume M, Schultz PG, Kay SA, Takahashi JS, Hogenesch JB (2002) Coordinated transcription of key pathways in the mouse by the circadian clock. Cell 109:307–320
Pogue-Geile KL, Lyons-Weiler J, Whitcomb DC (2006) Molecular overlap of fly circadian rhythms and human pancreatic cancer. Cancer Lett 243:55–57
Raedler LA (2016) Farydak (Panobinostat): first HDAC inhibitor approved for patients with relapsed multiple myeloma. Am Health Drug Benefits 9:84–87
Rafnsson V, Tulinius H, Jonasson JG, Hrafnkelsson J (2001) Risk of breast cancer in female flight attendants: a population-based study (Iceland). Cancer Causes Control 12:95–101
Ramsey KM, Yoshino J, Brace CS, Abrassart D, Kobayashi Y, Marcheva B, Hong HK, Chong JL, Buhr ED, Lee C et al (2009) Circadian clock feedback cycle through NAMPT-mediated NAD+ biosynthesis. Science 324:651–654
Relles D, Sendecki J, Chipitsyna G, Hyslop T, Yeo CJ, Arafat HA (2013) Circadian gene expression and clinicopathologic correlates in pancreatic cancer. J Gastrointest Surg 17:443–450
Reppert SM, Weaver DR (2002) Coordination of circadian timing in mammals. Nature 418:935–941
Ripperger JA, Schibler U (2006) Rhythmic CLOCK–BMAL1 binding to multiple E-box motifs drives circadian Dbp transcription and chromatin transitions. Nat Genet 38:369–374
Røe OD, Anderssen E, Helge E, Pettersen CH, Olsen KS, Sandeck H, Haaverstad R, Lundgren S, Larsson E (2009) Genome-wide profile of pleural mesothelioma versus parietal and visceral pleura: the emerging gene portrait of the mesothelioma phenotype. PLoS ONE 4:e6554
Sawicka A, Seiser C (2014) Sensing core histone phosphorylation. A matter of perfect timing. Biochim Biophys Acta 1839:711–718
Schernhammer ES, Laden F, Speizer FE, Willett WC, Hunter DJ, Kawachi I, Colditz GA (2001) Rotating night shifts and risk of breast cancer in women participating in the nurses’ health study. J Natl Cancer Inst 93:1563–1568
Schernhammer ES, Holly JM, Hunter DJ, Pollak MN, Hankinson SE (2006) Insulin-like growth factor-I, its binding proteins (IGFBP-1 and IGFBP-3), and growth hormone and breast cancer risk in The Nurses Health Study II. Endocr Relat Cancer 13:583–592
Sharrard RM, Royds JA, Rogers S, Shorthouse AJ (1992) Patterns of methylation of the c-myc gene in human colorectal cancer progression. Br J Cancer 65:667–672
Shih MC, Yeh KT, Tang KP, Chen JC, Chang JG (2006) Promoter methylation in circadian genes of endometrial cancers detected by methylation-specific PCR. Mol Carcinog 45:732–740
Siavoshian S, Segain JP, Kornprobst M, Bonnet C, Cherbut C, Galmiche JP, Blottière HM (2000) Butyrate and trichostatin A eVects on the proliferation/diVerentiation of human intestinal epithelial cells: induction of cyclin D3 and p21 expression. Gut 46:507–514
Spanhoff A, Hauser AT, Heike R, Sippl W, Jung M (2009) The emerging therapeutic potential of histone methyltransferase and demethylase inhibitors. Chem Med Chem 4:1568–1582
Sun CM, Huang SF, Zeng JM, Liu DB, Xiao Q, Tian WJ, Zhu XD, Huang Z, Feng WL (2010) Per2 inhibits k562 leukemia cell growth in vitro and in vivo through cell cycle arrest and apoptosis induction. Pathol Oncol Res 16:403–411
Takahata S, Ozaki T, Mimura J, Kikuchi Y, Sogawa K, Fujii-Kuriyama Y (2000) Transactivation mechanisms of mouse clock transcription factors, mClock and mArnt3. Genes Cells 5:739–747
Tamai TK, Young LC, Cox CA, Whitmore D (2012) Light acts on the zebrafish circadian clock to suppress rhythmic mitosis and cell proliferation. J Biol Rhythms 27:226–236
Tanaka S, Arii S, Yasen M, Mogushi K, Su NT, Zhao C, Imoto I, Eishi Y, Inazawa J, Miki Y, Tanaka H (2008) Aurora kinase B is a predictive factor for the aggressive recurrence of hepatocellular carcinoma after curative hepatectomy. Br J Surg 95:611–619
Taniguchi H, Fernandez AF, Setien F, Ropero S, Ballestar E, Villanueva A, Yamamoto H, Imai K, Shinomura Y, Esteller M (2009) Epigenetic inactivation of the circadian clock gene BMAL1 in hematologic malignancies. Cancer Res 69:8447–8454
Tokunaga H, Takebayashi Y, Utsunomiya H, Akahira J, Higashimoto M, Mashiko M, Ito K, Niikura H, Takenoshita S, Yaegashi N (2008) Clinicopathological significance of circadian rhythm-related gene expression levels in patients with epithelial ovarian cancer. Acta Obstet Gynecol Scand 87:1060–1070
Unsal-Kacmaz K, Mullen TE, Kaufmann WK, Sancar A (2005) Coupling of human circadian and cell cycles by the timeless protein. Mol Cell Biol 25:3109–3116
Vachtenheim J, Horakova I, Novotna H (1994) Hypomethylation of CCGG sites in the 3' region of H-ras protooncogene is frequent and is associated with H-ras allele loss in non-small cell lung cancer. Cancer Res 54:1145–1148
Van Dycke KC, Rodenburg W, Van Oostrom CT, VanKerkhof LW, Pennings JL, Roenneberg T, Van Steeg H, Vanderhorst GT (2015) Chronically alternating light cycles increase breast cancer risk in mice. Curr Biol 25:1932–1937
Vincenzi B, Santini D, La Cesa A, Tonini G (2003) Cancer chronotherapy: principles, applications, and perspectives. Cancer 98:881–882
Wang Y, Qian R, Sun N, Lu C, Chen Z, Hua L (2015) Circadian gene hClock enhances proliferation and inhibits apoptosis of human colorectal carcinoma cells in vitro and in vivo. Mol Med Rep 11:4204–4210
Wood PA, Yang X, Taber A, Oh EY, Ansell C, Ayers SE, Al-Assaad Z, Carnevale K, Berger FG, Peña M, Hrushesky W (2008) Period 2 Mutation accelerates ApcMin/+ tumorigenesis. Mol Cancer Res 6:1786–1793
Xia H, Niu Z, Ma H, Cao SZ, Hao SC, Liu ZT, Wang F (2010) Deregulated expression of the Per1 and Per2 in human gliomas. Can J Neurol Sci 37:365–370
Xia L, Ma S, Zhang Y, Wang T, Zhou M (2015) Daily variation in global and local DNA methylation in mouse livers. PLoS ONE 10:e0118101
Xiang S, Coffelt SB, Mao L, Yuan L, Cheng Q (2008) Period-2: a tumor suppressor gene in breast cancer. J Circadian Rhythms 6:4
Xiao H, Hasegawa T, Isobe K (2000) p300 collaborates with Sp1 and Sp3 in p21 (waf1/cip1) promoter activation induced by histone deacetylase inhibitor. J Biol Chem 275:1371–1376
Yang J, Kawai Y, Hanson RW, Arinze IJ (2001) Sodium butyrate induces transcription from the G alpha(i2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. J Biol Chem 276:25742–25752
Yang MY, Chang JG, Lin PM, Tang KP, Chen YH, Lin HY, Liu TC, Hsiao HH, Liu YC, Lin SF (2006) Downregulation of circadian clock genes in chronic myeloid leukemia: alternative methylation pattern of hPER3. Cancer Sci 97:1298–1307
Yang X, Wood PA, Oh EY, Du-Quiton J, Ansell CM, Hrushesky WJ (2009) Down regulation of circadian clock gene Period 2 accelerates breast cancer growth by altering its daily growth rhythm. Breast Cancer Res Treat 117:423–431
Yang MY, Yang WC, Lin PM, Hsu JF, Hsiao HH, Liu YC, Tsai HJ, Chang CS, Lin SF (2011) Altered expression of circadian clock genes in human chronic myeloid leukemia. J Biol Rhythms 26:136–148
Ye Y, Xiang Y, Ozguc FM, Kim Y, Liu CJ, Park PK, Hu Q, Diao L, Lou Y, Lin C (2018) The genomic landscape and pharmacogenomic interactions of clock genes in cancer chronotherapy. Cell Syst 6:314–328.e2
Yeh KT, Yang MY, Liu TC, Chen JC, Chan WL, Lin SF, Chang JG (2005) Abnormal expression of period 1 (PER1) in endometrial carcinoma. J Pathol 206:111–120
Zhang Y, Reinberg D (2001) Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 15:2343–2360
Zhou F, He X, Liu H, Zhu Y, Jin T, Chen C, Qu F, Li Y, Bao G, Chen Z, Xing J (2012) Functional polymorphisms of circadian positive feedback regulation genes and clinical outcome of Chinese patients with resected colorectal cancer. Cancer 118:937–946
Zhu Y, Leaderer D, Guss C, Brown HN, Zhang Y, Boyle P, Stevens RG, Hoffman A, Qin Q, Han X et al (2007) Ala394Thr polymorphism in the clock gene NPAS2: a circadian modifier for the risk of non-Hodgkin’s lymphoma. Int J Cancer 120:432–435
Zhu Y, Stevens RG, Hoffman AE, Fitzgerald LM, Kwon EM, Ostrander EA, Davis S, Zheng T, Stanford JL (2009) Testing the circadian gene hypothesis in prostate cancer: a population-based case-control study. Cancer Res 69:9315–9322
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Hernández-Rosas, F., López-Rosas, C.A. & Saavedra-Vélez, M.V. Disruption of the Molecular Circadian Clock and Cancer: An Epigenetic Link. Biochem Genet 58, 189–209 (2020). https://doi.org/10.1007/s10528-019-09938-w
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-019-09938-w